Legend Biotech (LEGN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
CARVYKTI net trade sales rose 36% YoY to $710M; Q3 revenue was $359.5M, up 32%, and adjusted net income was $55.6M.
FY26 adjusted profitability remains the target; priorities include expanding CARVYKTI access, advancing the pipeline and strengthening execution.
Ingrid Zhang became CEO effective September 15, 2026, succeeding interim CEO Alan Bash, who resumed his role as President, CARVYKTI.
Financial highlights
Q3 revenue was $359.5M versus $272.4M a year earlier; collaboration revenue was $353.2M, up 35%, and license and other revenue was $6.3M, down 41%.
Net income was $51.7M versus a $39.6M loss; adjusted net income was $55.6M versus an $18.7M adjusted loss.
Operating expenses fell 18% to $165.1M, including a $24M one-time share-based compensation credit; excluding it, expenses declined 6%.
R&D expense declined 16% to $95.3M; SG&A fell 20% to $69.8M, but rose 8% excluding the one-time credit.
Adjusted diluted EPS was $0.14 versus $(0.05); IFRS diluted EPS was $0.13 versus $(0.11).
Outlook and guidance
FY26 adjusted, company-wide profitability remains the target; CARVYKTI became profitable in 2025 under a product-profit definition based on net trade sales less cost of goods sold and operating expenses.
CARVYKTI is expected to deliver double-digit YoY growth in 2027; management described current 2027 sales consensus as high-end relative to anticipated scenarios.
2026 goals include three-quarters of CARVYKTI orders from 2L–4L, LB2501 IND clearance, in vivo data presentation and adjusted profitability.
CARTITUDE-5 readout is not expected before 2027; CARTITUDE-6 is expected later. Both studies are event-driven.
Latest events from Legend Biotech
- CARVYKTI growth and earlier-line evidence anchor 2026 profitability and pipeline ambitions.LEGN
Corporate presentation - CARVYKTIⓇ sales up 50% year-over-year, driving profitability and strong cash position.LEGN
Q2 2026 - Cilta-cel delivers strong survival gains and safer, more convenient treatment for myeloma patients.LEGN
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 - Earlier CARVYKTI use improves survival, safety, and access in multiple myeloma.LEGN
American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - CARVYKTIⓇ sales jumped 62% year-over-year, fueling revenue growth and margin improvement.LEGN
Q1 2026 - Q4 2025 CARVYKTI sales surged 66% YoY, driving profitability and global expansion.LEGN
Q4 2025 - Carvykti's growth accelerates with expanded capacity, strong efficacy, and promising pipeline advances.LEGN
Morgan Stanley 22nd Annual Global Healthcare Conference - CARVYKTI sales soared 135% year-over-year, fueling revenue growth and global expansion.LEGN
Q1 2025 - 2024 revenue surged and net loss narrowed, with CARVYKTI driving growth and strong cash reserves.LEGN
Q4 2024